BioPharma Dive July 28, 2021
- Ring Therapeutics, a startup developing a new method to deliver gene therapy products, has raised $117 million in a Series B financing.
- The startup creator that formed Moderna, Flagship Pioneering, is also the founding investor for Ring. Flagship participated in the Series B round alongside other firms including Invus, Altitude Life Science Ventures, Partners Investment and UPMC Enterprises.
- Ring said it will use the money to advance gene therapies that harness harmless anelloviruses present in the human body. The company says it has thousands of candidates for anello-based vectors that can be used to deliver therapies, though its work remains in early stages.
With Ring, Flagship is looking for another breakout star in the...